Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Leukemia, Myeloid, Acute 14Prostatic Neoplasms 10Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3HIV Infections 2Acquired Immunodeficiency Syndrome 2Sarcoma, Kaposi 1Recurrence 1Pain 1Myeloid Malignancies 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Leukemia, Lymphoid 1Dendritic Cell Sarcoma, Interdigitating 1Androgen-independent Prostate Cancer 1

Interventions

Mitoxantrone 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Androgen-independent Prostate Cancer × Mitoxantrone × Clear all
NCT00661492 2016-12-09

Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)

US Oncology Research

Phase 2 Completed
115 enrolled 16 charts
Genitourinary

Androgen-independent Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡